INDIA—Hindustan Syringes and Medical Devices (HMD), a renowned Indian medical device maker, has just introduced the Dispojekt range of syringes, which have safety needles and a Sharps Injury Prevention shield.
HMD’s pioneering Dispojekt safety syringes are designed to reduce the occurrence of accidental Needle Stick Injuries (NSIs) among healthcare workers, thus minimizing expenses related to infection control, disposal, and training. This initiative promises long-term financial benefits to the healthcare sector.
Manufactured domestically and incorporating advanced technology, these syringes provide India with a competitive edge in research and development, surpassing indigenous businesses in the global market for sharp injury prevention syringes.
The adoption of safety needles in healthcare settings offers significant economic advantages by lowering healthcare worker injuries, reducing expenses for potential disease treatment, and mitigating long-term health issues.
Rajiv Nath, Managing Director of HMD, emphasized during the launch that the Dispojekt syringe, equipped with a safety shield (SIP Shield), addresses major concerns regarding needle stick injuries.
He reiterated HMD’s commitment to healthcare excellence and positioned India on track to become a global leader in medical equipment production and exportation, aligning with the ethos of Atma Nirbhar Bharat.
Regarding the safety and efficacy of Dispojekt safety needle syringes, Rajiv highlighted that they are part of Safety Engineered Devices (SED), backed by numerous clinical studies and evaluations.
Clinical trials have demonstrated a reduction in needle stick injuries among healthcare professionals, endorsing the use of SED as best practice for injection safety by organizations like the EU, the United States, and the WHO.
On his part, Executive Director Sohail Nath outlined HMD’s ambitious goals, aiming for a 60–70 percent market share within three years with the introduction of Dispojekt.
The company plans to initially produce 200 million syringes and needles annually, investing around Rs 70 crore (US$8.459 million) in the first phase, with expansion to 300 million pieces per year in the second phase with an additional investment of Rs 10 crore to Rs 15 crore (US$1.208 million to US$1.812million).
Sohail emphasized that these syringes will not only strengthen HMD’s market position but also contribute to global efforts to combat NSIs and blood-borne diseases, aligning with WHO’s objectives.
Sohail further emphasized the affordability of Dispojekt safety needle syringes, designed to cater to underdeveloped regions like India, costing approximately half the price of safety single-use syringes in the US and Europe.
HMD, renowned for its cutting-edge manufacturing facilities in Faridabad, Haryana, is a leading medical device manufacturer, producing over 4 billion injection needles annually for primary markets in India, Europe, the United States, the Middle East, and secondary markets in South-East Asia and Africa.
In India, HMD maintains a robust distribution network, ensuring uninterrupted supply chain management with over 9500 dealers and 60 contractual stock points across key metropolitan, tier I, and tier II cities.
This network, supported by a dedicated sales force, ensures swift delivery and short turnaround cycles, mirroring the success of its Dispovan brand syringes.
The introduction of Dispojekt safety needle syringes is crucial given the significant prevalence of NSIs among healthcare personnel.
With just 10% of NSI injuries reported, and the highest global HIV prevalence in underdeveloped nations, the need for innovative solutions like Dispojekt is paramount.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
